Welcome to our dedicated page for Medicinova news (Ticker: MNOV), a resource for investors and traders seeking the latest updates and insights on Medicinova stock.
MediciNova, Inc. develops small-molecule therapeutics for inflammatory, fibrotic, and neurodegenerative diseases. The company's recurring updates center on MN-166, or ibudilast, and MN-001, or tipelukast, including programs involving amyotrophic lateral sclerosis, degenerative cervical myelopathy, progressive multiple sclerosis, chemotherapy-induced peripheral neuropathy, Long COVID, substance dependence, non-alcoholic fatty liver disease, hypertriglyceridemia, and idiopathic pulmonary fibrosis.
MediciNova news also covers clinical-trial progress, expanded-access activity, investigator-sponsored research, peer-reviewed translational studies, scientific and regulatory advisory matters, and corporate updates connected to its Nasdaq-listed common stock and Tokyo Stock Exchange listing.
MediciNova (NASDAQ: MNOV) reported that it has reached the target enrollment of 200 ALS patients in the NIH‑funded SEANOBI‑ALS Expanded Access Program (NCT06743776) evaluating MN‑166 (ibudilast). The program provides access to MN‑166 for individuals with ALS who are not eligible for randomized clinical trials.
According to MediciNova, all active participants remain on treatment and protocol‑specified follow‑ups, with final follow‑ups projected to conclude in early 2027, after which data analysis is planned to support scientific presentations and publications. MN‑166, an oral small‑molecule inhibitor of PDE4 and inflammatory cytokines, is being studied across multiple neuroinflammatory and neurodegenerative indications, including ALS. The company previously completed enrollment in its COMBAT‑ALS Phase 2b/3 trial of MN‑166 in September 2025.
MediciNova (NASDAQ: MNOV) issued a CEO shareholder update outlining clinical, IP, and investor-relations progress in 2026.
Key items include Phase 2 LPLV completion for MN-001 in hypertriglyceridemia/NAFLD with T2DM, ongoing ALS SEANOBI enrollment for MN-166, a new U.S. patent allowance for ibudilast combinations through 2042, and expanded equity research coverage.
MediciNova (NASDAQ:MNOV) announced a U.S. Patent and Trademark Office Notice of Allowance for a patent covering ibudilast (MN-166) combined with anti-PD-1 immune checkpoint inhibitors for glioblastoma treatment. The allowed claims span multiple dosing parameters, and the patent, once issued, is expected to expire no earlier than September 2042.
MediciNova (NASDAQ:MNOV) completed last patient last visit in its Phase 2 MN-001-NATG-202 trial of MN-001 (tipelukast) for hypertriglyceridemia and NAFLD associated with type 2 diabetes.
The multicenter, randomized, double-blind, placebo-controlled study compares 500 mg/day MN-001 versus placebo over 24 weeks, with top-line data expected in Q3 2026.
MediciNova (NASDAQ: MNOV) announced a peer‑reviewed study (Cancer Research, Mar 2026) identifying a MIF–CD74 vulnerability in brain metastasis and showing that the brain‑penetrant small molecule ibudilast (MN‑166) can inhibit this pathway in preclinical models.
The study reports reduced metastatic progression with MIF–CD74 inhibition, identification of secreted MIF detectable in cerebrospinal fluid as a candidate biomarker, transcriptomic signatures tied to response, and planned collaboration with CNIO to advance translational clinical research.
MediciNova (NASDAQ: MNOV) will participate in the 38th Annual ROTH Conference March 22–24, 2026 at The Ritz-Carlton, Dana Point, CA.
President & CEO Yuichi Iwaki, M.D., Ph.D., and Chief Business Officer David H. Crean, Ph.D., will hold in-person one-on-one and small group meetings to provide company updates; investors should contact ROTH representatives to arrange meetings.
MediciNova (NASDAQ:MNOV) announced that as of January 2026, 100 patients have been enrolled in the NIH‑funded SEANOBI Expanded‑Access Program (EAP) evaluating MN‑166 (ibudilast) in ALS, representing 50% of the planned 200 enrollment across 12 activated US sites. The program is supported by a $22 million NINDS grant under ACT for ALS and will generate real‑world biomarker and clinical outcome data alongside the COMBAT‑ALS Phase 2b/3 randomized trial (234 patients enrolled; topline expected by end of 2026).
MediciNova (NASDAQ:MNOV) CEO Yuichi Iwaki delivered a New Year letter on Jan 6, 2026 outlining 2025 clinical progress and 2026 priorities.
Clinical highlights: enrollment completed in three trials—COMBAT‑ALS (MN‑166) completed enrollment Sept 2025 with top‑line results expected by year‑end; OXTOX Phase 2b completed enrollment Dec 2025; MN‑001 Phase 2 enrollment completed Nov 2025 with top‑line data anticipated summer 2026. An Expanded Access Program for ALS launched March 2025 supported by a $22 million NIH grant; as of Dec 15, 2025 there were 12 U.S. sites and 87 patients enrolled.
The company says 2026 will be pivotal as it prepares for potential regulatory submission if COMBAT‑ALS results are positive.
MediciNova (NASDAQ:MNOV) announced completion of patient enrollment in the randomized, placebo-controlled Phase 2 OXTOX study evaluating MN-166 (ibudilast) to prevent chemotherapy-induced peripheral neuropathy in metastatic colorectal cancer.
A total of 100 patients were randomized across two arms at 11 clinical sites in Australia. Patient recruitment is closed; participants continue chemotherapy with assigned study drug until disease progression or unacceptable toxicity. The study will conclude when the final patient reaches six months post-chemotherapy. Top-line data are anticipated later in 2026, though no exact completion date is provided.
MediciNova (NASDAQ:MNOV) reported an update from the COMBAT-ALS Phase 2b/3 trial of MN-166 (ibudilast) presented at the 36th International Symposium on ALS/MND (Dec 5–7, 2025).
Key facts: 234 participants randomized, enrollment completed Sept 2025. Baseline metrics: mean age 60.6, mean ALSFRS-R 40.6, mean disease duration 12.5 months. Sex split: 36.8% female, 63.2% male. Racial mix: Caucasian 90.2%, Asian 5.1%.
The company noted COVID-19–related enrollment challenges, is offering continued access via FDA individual expanded access, and cited FDA Orphan Drug and Fast Track designations and European orphan designation. Top-line data are anticipated by end of 2026.